Biotechnology company BIOCAD and the pharmaceutical corporation Shanghai Pharmaceuticals Holding Co., Ltd (SPH) used Eastern Economic Forum 2018 to sign a memorandum of understanding regarding the establishment of two joint ventures for the clinical development, registration and marketing of medicines based on monoclonal antibodies in the People’s Republic of China.
The main goal of the establishment of Russian-Chinese enterprises is the clinical development, production, registration and launch of at least 6 BIOCAD products used in advanced therapy of oncological and severe autoimmune diseases such as chronic lymphocytic leukemia, colorectal cancer, lung cancer, breast cancer, psoriasis, ankylosing spondylitis, etc.
“We expect that the localization of production in China will give impetus to the development of the export potential of the Russian pharmaceutical industry,” commented Dmitry Morozov, Director General of BIOCAD, “and will also enable the transfer of technology for the production of biological products to China in a short time, that will set a new direction for the development of cooperation between the two countries. “
Dmitry Morozov added that the joint ventures that are being created have no analogues and are the first large-scale project of Russian-Chinese cooperation in the pharmaceutical industry.